Pharmaceutical company Novo Nordisk will expand its production site in Montes Claros, Brazil, creating 600 jobs.

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 15 unusual trades. Delving into the details, we found 46% of ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

With a history dating back more than 100 years, Novo Nordisk has long been a leader in diabetes care. Its breakthrough came with the development of semaglutide, a GLP-1 receptor agonist.

Continue » Is it time to buy the dip in Novo Nordisk stock? Here's what you need to know. With a history dating back more than 100 years, Novo Nordisk has long been a leader in diabetes care.